Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Konstantin Kazankov

Showing results (1-10 of 39) with videos related to

Pageof 4
Sort By:
Expert Review of Gastroenterology & Hepatology|September 4, 2020
Current perspectives on the pathophysiology of metabolic associated fatty liver disease: are macrophages a viable target for therapy?Mikkel Breinholt Kjær, Jacob George, Konstantin Kazankov, et al.
The Lancet. Digital Health|November 21, 2024
The new digital era in decompensated cirrhosisKohilan Gananandan, Konstantin Kazankov, Elliot B Tapper, et al.
Scandinavian Journal of Gastroenterology|August 1, 2024
Risk factors for acute myocardial infarction in patients with alcohol-related cirrhosis - a Danish nested case-control studyEmma Celia Herting, Rasmine Birn-Rydder, Konstantin Kazankov, et al.
Ugeskrift for Laeger|February 22, 2012
[Prognosis and treatment of non-alcoholic fatty liver disease and steatohepatitis]Sara Heebøll, Konstantin Kazankov, Marianne Kjær Poulsen, et al.
Expert Opinion on Therapeutic Targets|October 7, 2022
Spotlight on liver macrophages for halting injury and progression in nonalcoholic fatty liver diseaseTea Lund Laursen, Anders Mellemkjær, Holger Jon Møller, et al.
World Journal of Gastroenterology|June 27, 2020
Liver-related effects of chronic hepatitis C antiviral treatmentTea L Laursen, Thomas D Sandahl, Konstantin Kazankov, et al.
Physiological Reports|January 18, 2022
Macrophage activation marker sCD163 is associated with liver injury and hepatic insulin resistance in obese patients before and after Roux-en-Y gastric bypassKonstantin Kazankov, Kirstine Nyvold Bojsen-Møller, Holger Jon Møller, et al.
Scandinavian Journal of Gastroenterology|October 15, 2019
QT interval corrected for heart rate is not associated with mortality in patients with cirrhosis and ascitesKonstantin Kazankov, Henrik Kjaerulf Jensen, Hugh Watson, et al.
Journal of Hepatology|September 30, 2020
Macrophage markers and innate immunity in cirrhosisHenning Grønbæk, Rasmus Hvidbjerg Gantzel, Tea Lund Laursen, et al.
Hepatology (Baltimore, Md.)|July 22, 2014
Reply: To PMID 24623375Konstantin Kazankov, Holger Jon Møller, Bo Martin Bibby, et al.
Pageof 4

Showing results (1-10 of 39) with videos related to

Sort By:
Pageof 4
Expert Review of Gastroenterology & Hepatology|September 4, 2020
Current perspectives on the pathophysiology of metabolic associated fatty liver disease: are macrophages a viable target for therapy?Mikkel Breinholt Kjær, Jacob George, Konstantin Kazankov, et al.
The Lancet. Digital Health|November 21, 2024
The new digital era in decompensated cirrhosisKohilan Gananandan, Konstantin Kazankov, Elliot B Tapper, et al.
Scandinavian Journal of Gastroenterology|August 1, 2024
Risk factors for acute myocardial infarction in patients with alcohol-related cirrhosis - a Danish nested case-control studyEmma Celia Herting, Rasmine Birn-Rydder, Konstantin Kazankov, et al.
Ugeskrift for Laeger|February 22, 2012
[Prognosis and treatment of non-alcoholic fatty liver disease and steatohepatitis]Sara Heebøll, Konstantin Kazankov, Marianne Kjær Poulsen, et al.
Expert Opinion on Therapeutic Targets|October 7, 2022
Spotlight on liver macrophages for halting injury and progression in nonalcoholic fatty liver diseaseTea Lund Laursen, Anders Mellemkjær, Holger Jon Møller, et al.
World Journal of Gastroenterology|June 27, 2020
Liver-related effects of chronic hepatitis C antiviral treatmentTea L Laursen, Thomas D Sandahl, Konstantin Kazankov, et al.
Physiological Reports|January 18, 2022
Macrophage activation marker sCD163 is associated with liver injury and hepatic insulin resistance in obese patients before and after Roux-en-Y gastric bypassKonstantin Kazankov, Kirstine Nyvold Bojsen-Møller, Holger Jon Møller, et al.
Scandinavian Journal of Gastroenterology|October 15, 2019
QT interval corrected for heart rate is not associated with mortality in patients with cirrhosis and ascitesKonstantin Kazankov, Henrik Kjaerulf Jensen, Hugh Watson, et al.
Journal of Hepatology|September 30, 2020
Macrophage markers and innate immunity in cirrhosisHenning Grønbæk, Rasmus Hvidbjerg Gantzel, Tea Lund Laursen, et al.
Hepatology (Baltimore, Md.)|July 22, 2014
Reply: To PMID 24623375Konstantin Kazankov, Holger Jon Møller, Bo Martin Bibby, et al.
Pageof 4